Form 4: Boston Scientific EVP Exercises Performance Share Units, Disposes of Shares

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, exercised performance share units and disposed of shares on January 1, 2025.

Summary

• On January 1, 2025, Joseph Michael Fitzgerald, an EVP at Boston Scientific, exercised 13,907 performance share units, each representing one share of Boston Scientific common stock.
• He also disposed of 6,425 shares at a price of $89.32 per share.
• Following these transactions, Fitzgerald directly owns 155,600 shares of Boston Scientific common stock.
• He also indirectly owns 4,894 shares through his child, but disclaims beneficial ownership of these shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing an executive's stock transactions, which is neutral in sentiment. It reflects routine compensation practices.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely watched by investors for insights into management's perspective on the company's performance and future prospects. This transaction reflects the vesting and exercise of previously awarded performance-based compensation.

Comparison to Industry Standards

• Executive compensation packages often include performance share units that vest based on company performance metrics, such as free cash flow, aligning executive incentives with shareholder value.
• The vesting period of three years is a typical timeframe for such awards, ensuring long-term commitment from the executive.
• Similar companies like Medtronic and Abbott also utilize performance-based equity compensation as part of their executive pay structure.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves the exercise of previously awarded equity and a small disposal of shares.
• The impact on employees is negligible as it pertains to an individual executive's compensation.

Key Dates